Drug-drug interaction: decreased posaconazole trough concentrations during concomitant flucloxacillin treatment

J Antimicrob Chemother. 2023 Jun 1;78(6):1471-1475. doi: 10.1093/jac/dkad107.

Abstract

Background and objectives: Posaconazole is used as prophylaxis of invasive fungal disease in immune-compromised haematological patients with prolonged neutropenia after intensive chemotherapy. During routine therapeutic drug monitoring of posaconazole, we repeatedly observed low posaconazole serum concentrations in patients that were concomitantly treated with flucloxacillin. A possible interaction between flucloxacillin and posaconazole was explored in this case series.

Patients and methods: Posaconazole trough serum concentrations during and before/after flucloxacillin treatment were collected from 10 patients.

Results: With a median concentration of 0.5 mg/L (IQR 0.3-0.6), the posaconazole trough serum concentration decreased by 47% during flucloxacillin treatment compared with the concentration before/after flucloxacillin treatment (0.9 mg/L, IQR 0.6-1.3). As a result, the posaconazole target trough concentration of ≥0.7 mg/L was only achieved in five out of nine patients during flucloxacillin treatment.

Conclusions: Careful monitoring of posaconazole serum trough concentrations is recommended when concomitant use of flucloxacillin cannot be avoided.

MeSH terms

  • Antifungal Agents / therapeutic use
  • Floxacillin / therapeutic use
  • Humans
  • Mycoses* / drug therapy
  • Retrospective Studies

Substances

  • Antifungal Agents
  • posaconazole
  • Floxacillin